To recover your password please fill in your email address
Please fill in below form to create an account with us
The ANZUP-led ENZAMET trial was a stand-out success story, with results presented in the Plenary session at the recent American Society of Clinical Oncology annual conference (ASCO19) in Chicago in early June 2019. CTC staff were heavily involved in the design, coordination and analysis of this international trial.
ENZAMET results were kept quiet until the presentation at the conference. Attendees learned that the trial found out a hormone therapy, called enzalutamide, could deliver a 33% survival benefit for men with metastatic prostate cancer. The results, which involved 1,125 male patients, were published in the New England Journal of Medicine (NEJM) at the same time as the conference.
“The ENZAMET clinical trial is testimony for a global collaboration to answer an important question that has generated clinically impactful data," said Co‐Chairs Prof. Christopher Sweeney and Prof. Ian Davis. "We are greatly encouraged by the ability of enzalutamide to increase the longevity of men with mHSPC. The data and the biological samples collected will guide future trials with the goal to make more advances.”
The CTC’s Martin Stockler and Andrew Martin were present and acknowledged in the presentation. They and the CTC's Xanthi Coskinas, Wendy Hague, Sonia Yip, Emily Tu and Alison Zhang were co-authors on the NEJM paper. A total of 22 staff from CTC’s Oncology and Translational Research divisions contributed to the ENZAMET trial.
Support was also provided by the Canadian Cancer Trials Group, Dana-Farber Cancer Institute, and Cancer Trials Ireland. Astellas Pharma provided drug and financial support, and the University of Sydney sponsored the trial.
Other CTC success at ASCO